About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
2BB score and signals
Sarepta Therapeutics, Inc.’s current 2BB score is 26 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 12 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 35 | Weak |
| Quality | 100 | Very Strong |
| Risk | 39 | Low |
Company facts
| CEO | Douglas S. Ingram |
| Founded | 1980 |
| Employees | 835 |
| P/E ratio | 165.12 |
| 52-week range | $10.42 – $25.32 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-23 | — | 0.0073 | — | $360.95M |
| 2026-11-04 | — | 0.1312 | — | $361.78M |
| 2026-08-05 | — | 0.2625 | — | $371.63M |
| 2026-05-04 | — | 1.1019 | — | $489.15M |
